Yu Jonathan Yen-Wen sold $66K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 804 shares of Disc Medicine, Inc. (IRON) at $82.64 on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Aug 14, 2026, 11:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 11:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly note insider selling, but 10b5-1 structure and small dollar value typically limit tradable signal strength.

03

What to watch

The transaction size is modest (about $66.4K) and the plan is pre-arranged, so it may not reflect a change in company outlook.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-14, sale dated 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold 804 shares in an open-market transaction at $82.6425 on 2026-08-12 under a 10b5-1 plan.

Expected impact

Likely minimal immediate impact; any effect would be sentiment-only and typically fades as 10b5-1 sales are expected.

Evidence & confidence

The filing is a Form 4 insider transaction, but it explicitly states a pre-arranged 10b5-1 plan, reducing the likelihood of new, non-public information driving the sale.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None.

None.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of valuation or liquidity management, which some traders may still interpret as caution.

Key entities

  • Disc Medicine, Inc.

    Company whose insider transaction was disclosed on Form 4.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRONHighAI 9/10

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update • Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints • Bitopertin NDA resubmission planned by e

$IRONHighAI 9/10

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants October 19, 2026 WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on

$IRONHighAI 8/10

Why is Disc Medicine stock sliding today?

Disc Medicine (IRON) stock fell 1.0% in pre-market trading after pricing a $450M public offering of 6M shares at $75 each, a discount to recent prices. The offering, with potential for additional shares, may dilute existing holders. Proceeds will fund clinical development and general corporate purposes. Analysts recently raised price targets following positive trial results, but insiders have been net sellers.